KRAS and non-small cell lung carcinoma: In contrast, NSCLC patients with KRAS mutation do not respond to the EGFR tyrosine kinase inhibitors (TKIs) mentioned above, even those with concurrent sensitive EGFR mutation, which could be attributed to continuous activation of the downstream Raf‐MEK‐ERK pathway.9